Tekmira Pharmaceuticals Corp. has entered into a product development agreement with Roche to advance Roche’s first two RNA interference (RNAi) product candidates into human trials. Both of the product candidates will be based on Tekmira’s stable nucleic acid-lipid particle (SNALP) technology. Under the terms of the agreement, Roche will pay Tekmira as much as $18.4 million to support IND applications for the product candidates. Tekmira is also eligible to receive as much as $32 mi...